NYLIM
EGRX

New York Life Investment Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

New York Life Investment Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,460
Closed -$335K – 1424
2022
Q4 		$335K Buy
11,460
+1,290
+13% +$41K ﹤0.01% 1100
2022
Q3 		$269K Buy
10,170
+747
+8% +$27.4K ﹤0.01% 1134
2022
Q2 		$419K Buy
+9,423
New +$433K ﹤0.01% 897

Other funds holding EGRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

New York Life Investment Management's EGRX Position: Q1 2023 in Review

New York Life Investment Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2023, closing a stake of 11,460 shares — an estimated $335K sold.

New York Life Investment Management first reported a position in EGRX in Q2 2022 and held it in 3 quarters. The position peaked at $419K in Q2 2022. 153 funds tracked by Wall St. Rank hold EGRX as of Q1 2023.

  • New York Life Investment Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 11,460 Eagle Pharmaceuticals, Inc. shares in Q1 2023, an estimated $335K.
  • New York Life Investment Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Eagle Pharmaceuticals, Inc. position peaked at $419K in Q2 2022.
  • 153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.